Teva Pharma Q3 Beats Market, Lifts FY24 Outlook
Teva Pharma Q3 Beats Market, Lifts FY24 Outlook; Stock Up
(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) Wednesday reported a loss in its third quarter, compared to prior year's profit, despite higher revenues. However, adjusted earnings and top line beat market estimates, and the firm lifted its fiscal 2024 forecast.
TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today ...
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their ...
UBS walked away from meetings with Teva (TEVA) management confident that the firm’s bullish thesis with a Street-high price target of $26 ...
JERUSALEM (Reuters) - Teva Pharmaceutical Industries expects to work productively with the incoming Trump administration in ...
Teva Pharmaceutical Industries Ltd (TEVA) reports a 15% revenue increase and raises 2024 guidance, despite facing legal and ...
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) will be announcing its earnings results before the market opens ...
In terms of liquidity and interest, the mean open interest for Teva Pharmaceutical Indus options trades today is 8263.67 with ...
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new patient- and physician-reported ...
QRG Capital Management Inc. cut its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 1.6% during the third quarter, according to the company in its most recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback